deferasirox has been researched along with Diarrhea in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aydinok, Y; Cappellini, MD; Joaquin, V; Karakas, Z; Kattamis, A; Lai, YR; Porter, JB; Siritanaratkul, N; Taher, AT; Uwamahoro, MJ; Viprakasit, V; Wang, C; Zhu, Z | 1 |
| Balez, S; Brun, E; Dumortier, T; Dutreix, C; Morisson, S; Pommier, F; Séchaud, R | 1 |
2 trial(s) available for deferasirox and Diarrhea
| Article | Year |
|---|---|
Optimising iron chelation therapy with deferasirox for non-transfusion-dependent thalassaemia patients: 1-year results from the THETIS study.
Topics: Adolescent; Adult; Benzoates; Blood Transfusion; Chelation Therapy; Child; Deferasirox; Diarrhea; Drug Administration Schedule; Drug Dosage Calculations; Female; Follow-Up Studies; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Middle Aged; Nausea; Thalassemia; Treatment Outcome; Triazoles | 2016 |
Relative bioavailability of deferasirox tablets administered without dispersion and dispersed in various drinks.
Topics: Administration, Oral; Adult; Area Under Curve; Benzoates; Beverages; Biological Availability; Chromatography, High Pressure Liquid; Citrus sinensis; Cross-Over Studies; Deferasirox; Diarrhea; Drug Stability; Half-Life; Humans; Iron Chelating Agents; Male; Malus; Tablets; Tandem Mass Spectrometry; Triazoles; Water | 2008 |